Literature DB >> 32745907

Fluvastatin and atorvastatin induce programmed cell death in the brain eating amoeba Naegleria fowleri.

Aitor Rizo-Liendo1, Ines Sifaoui2, Iñigo Arberas-Jiménez1, María Reyes-Batlle2, José E Piñero3, Jacob Lorenzo-Morales4.   

Abstract

Naegleria fowleri is the causative agent of a type of encephalitis called Primary Amoebic Encephalitis (PAM). Almost 98 % of PAM cases reported worldwide are fatal and affect mostly immunocompetent children and young adults. The current therapeutic option against PAM cases includes a combination of miltefosine, amphotericin B and other drugs which are unfortunately associated with severe side effects. In a recent study in our group, statins were tested in vitro against Naegleria fowleri trophozoites showing activity against these pathogens at low concentrations causing low toxicity. Consequently, there is an urgent need to develop novel PAM therapeutic options. Therefore, this study was undertaken to evaluate the pathway of cell death induced by two of the previously tested molecules, fluvastatin and atorvastatin. Moreover, these statins were compared to miltefosine and amphotericin B. Furthermore, the induction of Programmed Cell Death (PCD) instead of necrosis in treated amoebae would be the ideal situation since necrosis could lead to non-desired inflammation processes in the infected individual. The obtained results revealed that both statins induced PCD in the treated amoebae after the observation of condensed chromatin, cell membrane damages, mitochondrial membrane potential and ATP levels collapse and ROS generation. In conclusion, both fluvastatin and atorvastatin could be potential new candidates for PAM therapy since they are active at low concentrations, induce low toxicity and cause PCD in the treated amoebae, hence avoiding the activation of inflammation pathways.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Atorvastatin; Fluvastatin; Naegleria; PCD; Statins; Therapy

Mesh:

Substances:

Year:  2020        PMID: 32745907     DOI: 10.1016/j.biopha.2020.110583

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Opportunistic free-living amoebal pathogens.

Authors:  Mohammad Ridwane Mungroo; Naveed Ahmed Khan; Sutherland Maciver; Ruqaiyyah Siddiqui
Journal:  Pathog Glob Health       Date:  2021-10-02       Impact factor: 3.735

2.  Naegleria fowleri: Protein structures to facilitate drug discovery for the deadly, pathogenic free-living amoeba.

Authors:  Logan Tillery; Kayleigh Barrett; Jenna Goldstein; Jared W Lassner; Bram Osterhout; Nathan L Tran; Lily Xu; Ryan M Young; Justin Craig; Ian Chun; David M Dranow; Jan Abendroth; Silvia L Delker; Douglas R Davies; Stephen J Mayclin; Brandy Calhoun; Madison J Bolejack; Bart Staker; Sandhya Subramanian; Isabelle Phan; Donald D Lorimer; Peter J Myler; Thomas E Edwards; Dennis E Kyle; Christopher A Rice; James C Morris; James W Leahy; Roman Manetsch; Lynn K Barrett; Craig L Smith; Wesley C Van Voorhis
Journal:  PLoS One       Date:  2021-03-24       Impact factor: 3.240

3.  Statins Induce Actin Cytoskeleton Disassembly and an Apoptosis-Like Process in Acanthamoeba spp.

Authors:  Rubén L Rodríguez-Expósito; Ines Sifaoui; María Reyes-Batlle; Sutherland K Maciver; José E Piñero; Jacob Lorenzo-Morales
Journal:  Antibiotics (Basel)       Date:  2022-02-21

4.  A Fluorometric Assay for the In Vitro Evaluation of Activity against Naegleria fowleri Cysts.

Authors:  Iñigo Arberas-Jiménez; Aitor Rizo-Liendo; Ines Sifaoui; Javier Chao-Pellicer; José E Piñero; Jacob Lorenzo-Morales
Journal:  Microbiol Spectr       Date:  2022-07-11

Review 5.  Primary Amoebic Meningoencephalitis by Naegleria fowleri: Pathogenesis and Treatments.

Authors:  Andrea Güémez; Elisa García
Journal:  Biomolecules       Date:  2021-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.